Introduction: Isavuconazole is a new triazole approved for the treatment of invasive aspergillosis. We investigated isavuconazole MIC distributions, isavuconazole MIC correlations with those of other azoles and pharmacodynamics of isavuconazole in low-level resistant Aspergillus fumigatus isolates.
Introduction
Invasive aspergillosis is a fungal disease affecting mainly immunocompromised patients. 1 Currently, the mainstay of therapy for invasive aspergillosis is voriconazole, 2 but the use of voriconazole may be limited due to drug-drug interactions, toxicity and its large inter-and intra-individual variability. 3, 4 Isavuconazole is a relatively new triazole, with in vitro activity against Aspergillus species, yeasts and dimorphic fungi, 5 but low activity against species belonging to the Mucorales. 5, 6 In addition to its extended spectrum compared with voriconazole, isavuconazole has linear pharmacokinetics 7 and is less prone to be the perpetrator drug or victim drug in the setting of drug-drug interactions with concomitantly administered drugs. 5 Recently, isavuconazole was found to be non-inferior to voriconazole for the treatment of invasive fungal infections, but with fewer documented drug-related adverse effects. 8 Based on these results, the US FDA approved isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis. Later, the EMA also approved isavuconazole for the primary treatment of invasive aspergillosis and for the treatment of mucormycosis in patients for whom amphotericin B is inappropriate.
Following this approval, EUCAST published clinical breakpoints for isavuconazole, with isolates with an MIC of 1 mg/L to be classified as susceptible. 9 Importantly, the EUCAST clinical breakpoint is one step lower than the epidemiological cut-off (ECOFF), which is V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
2 mg/L. 9 As a direct consequence, part of the WT Aspergillus fumigatus population will be classified as resistant to isavuconazole based on this clinical breakpoint. 10 The rationale for this decision was based on Monte Carlo simulations 10,11 and a target derived from a mouse model of disseminated aspergillosis. 12 The probability of target attainment (PTA) in this analysis was $75% when the isavuconazole MIC for an isolate was 2 mg/L compared with nearly 100% when the isavuconazole MIC was 1 mg/L. 9,10 However, the clinical breakpoint is established using standard dosing: a loading dose of 200 mg three times daily (intravenous or oral) for 2 days followed by 200 mg (intravenous or oral) once daily. As the efficacy of isavuconazole was found to be concentration dependent and primarily dependent on the AUC/MIC ratio, [12] [13] [14] we hypothesized that administration of a higher dose can be used in order to treat patients infected by A. fumigatus with an isavuconazole MIC of 2 mg/L (one 2-fold dilution step above the breakpoint).
The first objective of this study was to analyse the implications of the EUCAST breakpoints when these are applied to a large prospectively collected dataset of A. fumigatus MICs. Secondly, we studied the correlation between isavuconazole MICs and those of other azoles. A previous study using a small number of selected isolates with known azole resistance mechanisms indicated that the isavuconazole MIC for A. fumigatus was highly correlated with voriconazole MICs when tested with CLSI methodology. 15 Thirdly, we investigated whether isavuconazole dose escalation would be a feasible option for the management of A. fumigatus infection with an isavuconazole MIC above the clinical breakpoint based on the model published by Desai et al. 11 Finally, we determined the correlation between C trough and AUC in order to establish C trough targets as surrogate markers for AUC to use in daily practice for the potential use of therapeutic drug monitoring.
Materials and methods

Isolates
A total of 487 consecutive clinical A. fumigatus isolates were used in this study. All isolates were prospectively collected between May 2014 and December 2015. As the Radboud University Medical Centre (UMC) serves as a national mycology reference centre, the collection also contained a large subset of isolates with non-WT phenotypes. All isolates were confirmed to be A. fumigatus species complex by microscopy and assessment of thermotolerance at 48 C.
Susceptibility testing
MICs of voriconazole, itraconazole, posaconazole and isavuconazole were routinely determined according to the EUCAST document E.Def 9.2 16 when an isolate was cultured from clinical material at the Radboud UMC, or at the time that an isolate was received at the laboratory from another hospital. Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used as quality control for susceptibility testing.
Agar-based azole resistance screening
Several of the laboratories that send isolates to our centre use an agarbased azole resistance screening method (VIPcheck TM , Nijmegen, The Netherlands) to screen for azole resistance in A. fumigatus isolates. Isolates that grow on azole-containing agar are then sent to the reference laboratory for MIC testing. Therefore, the collection of isolates does not reflect the current resistance rate in the Netherlands, as this collection is already preselected by screening.
Categorization of isolates
Isolates were categorized phenotypically as WT, 'non-WT non-resistant (non-WT-NR)' and non-WT resistant based on the EUCAST ECOFFs of voriconazole, itraconazole and posaconazole (. 
cyp51A sequencing
The cyp51A gene and promoter region were sequenced for all non-WT resistant isolates to determine the resistance mechanism as described previously. 18 We have extensive experience with sequencing the cyp51A gene of phenotypically WT isolates and isolates categorized as non-WT-NR. To date we have not found any mutations conferring azole resistance in the cyp51A gene in these isolates. To confirm this observation in our current dataset, we randomly selected 27 (%10%) phenotypically WT and 8 (%20%) isolates categorized as non-WT-NR and sequenced the cyp51A gene. We did not find cyp51A resistance mutations in these randomly selected isolates.
Correlation of isavuconazole MICs with those of other triazoles
The correlation between the isavuconazole MIC and the MICs of voriconazole, itraconazole and posaconazole was determined using the Spearman's correlation coefficient. Analysis was performed on all isolates as a group, as well as for the subgroups WT and non-WT and subsubgroups non-WT-NR, TR34/L98H, TR46/Y121F/T289A and non-WT isolates with other mutations as a group. Furthermore, the percentages of agreement of isavuconazole MICs and voriconazole, itraconazole and posaconazole MICs within one 2-fold dilution were calculated.
Monte Carlo simulations
Monte Carlo simulations were performed using non-linear mixed effects modelling (NONMEM) version 7.3.0 with the PiranaJS version 1.01 interface. 19 The model used for simulation is based on the model of Desai et al.
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Briefly, a two-compartment model with Weibull absorption and a fixed bioavailability of 1 is used. The values for variability are 62.44% for clearance in patients, 31.78% for volume of distribution of the peripheral compartment, 49.09% for inter-compartmental clearance and for the Weibull absorption model 40.24% for rate constant (RA) and 45.71% for gamma (GAM1). Simulations were performed using the characteristics (length and weight) of a representative group of 1706 haematology patients, from our hospital. 20 Three different dosing regimens were simulated (1706 patients representing the Radboudumc population for each regimen): I, loading dose of 3%200 mg for 2 days followed by 200 mg once daily; II, loading dose of 3%300 mg for 2 days followed by 300 mg once daily; and III, loading dose of 3%400 mg for 2 days followed by 400 mg once daily. The simulated AUC 0-24 and C trough were derived from the NONMEM model at day 28.
PTA
The pharmacokinetic/pharmacodynamic target for isavuconazole for the treatment of invasive aspergillosis was determined previously. 12 The target 
Correlation between AUC and C trough
For clinical management a C trough is preferred over AUC as it requires a single sampling moment and is thus more convenient/patient friendly and more easily obtained. For this purpose the C trough -AUC relation was calculated and the function of this correlation was determined using linear regression. This function was used to calculate the trough concentration (C trough ) corresponding to the target AUC 0-24 .
Statistics
All calculations and Monte Carlo simulations were performed using SPSS (version 21) and Graphpad Prism (version 5.03). The correlation between isavuconazole and itraconazole, posaconazole and voriconazole was determined with Spearman's rank coefficient (two-tailed). The figures were prepared with SPSS, Graphpad Prism and Excel (2007).
Results
Classification of isolates
Overall, 208 of 487 A. fumigatus isolates (43%) were categorized as isavuconazole non-WT ( 
cyp51A genotype
Sequencing of the cyp51A of non-WT resistant isolates revealed a mutation associated with azole resistance in 146/171 isolates (85%; Table 1 ). For 25 isolates (15%) no mutations in the cyp51A gene that are proven to cause azole resistance were found, indicating resistance mechanisms at other loci. These isolates were not further investigated for non-cyp51A-related mutations. 21, 22 As expected, sequencing the cyp51A gene of a randomly selected collection of WT and non-WT-NR isolates did not reveal any mutations that are associated with azole resistance, and therefore the cyp51A gene of the other WT and non-WT-NR isolates was not sequenced. However, one isolate had an N258K mutation and one isolate had the F46Y/M172V/E427K mutation, which were previously found in isolates with a WT phenotype as well. 23 
Antifungal susceptibility
The isolates were first grouped based on the classification of the isolates. Non-WT resistant isolates were further grouped based on the cyp51A mutations (Table 1) . Isavuconazole MIC distributions for these groups are displayed in Figure 1 . The EUCAST clinical breakpoints and ECOFFs for isavuconazole are displayed in the graphs; 25/279 phenotypically WT isolates (9%) were classified as isavuconazole resistant based on the EUCAST breakpoint. MICs of 277/279 isolates (99%) were below the ECOFF. All isolates harbouring the TR 34 /L98H mutation were resistant to isavuconazole, with MICs between 4 and .16 mg/L. All but one isolate with the TR 46 /Y121F/T289A mutation had an isavuconazole MIC of .16 mg/L. Isolates with a G54 mutation are often susceptible to voriconazole, which was also the case for the isolate with the G54R mutation in our study: voriconazole and isavuconazole MICs were 1 mg/L. Non-WT-NR isolates (n " 37) had higher isavuconazole MICs compared with WT isolates. The isavuconazole MICs ranged between 1 and 4 mg/L, compared with 0.125 and 4 mg/L for WT isolates. Twenty-nine of 37 (78%) of these isolates would be categorized as resistant to isavuconazole based on the EUCAST clinical breakpoint (Figure 1a and b) . In total, 196/208 (94%) of non-WT isolates were resistant to isavuconazole. 
Simulations of pharmacokinetics
Population pharmacokinetic simulations were performed to estimate the exposure obtained with the three dosing regimens. The AUC 0-24 values at steady state (day 28) are shown in Figure 3 . The median AUC 0-24 values were 82, 124 and 165 mgÁh/L for dosing regimens I, II and II, respectively. The 10% percentile AUC 0-24 values were estimated to be 37, 56 and 74 mgÁh/L, respectively.
PTA
The PTAs based on the Monte Carlo simulations for regimens I, II and III at steady state are shown in Figure 4 . The PTA increased with an increasing dose, as expected. The PTAs for isolates with an MIC of 1 mg/L were 97%, 99% and 100% for EC 50 and 92%, 98% and 99% for EC 90 for regimens I, II and III, respectively. For isolates with an MIC value of 2 mg/L, the PTA decreased to 81%, 93% and 97% for EC 50 and 64%, 85% and 92% for EC 90 . 
Correlation between AUC and C trough
We found a strong correlation between isavuconazole C trough and AUC 0-24 at steady state. The relationship between the parameters can be described by the function AUC 0-24 " 10.2!24.48 C trough. The calculated target C trough values are shown in Table 2 for MICs ranging between 0.25 and 8 mg/L.
Discussion
The first objective of this study was to apply the EUCAST breakpoints to a large set of clinical A. fumigatus isolates, which contained both WT and triazole-resistant isolates. To create a WT MIC distribution for isavuconazole, the WT isolates needed to be distinguished from the non-WT isolates. Isolates with solitary isavuconazole resistance without cross-resistance to any of the other azoles have not yet been reported. Therefore, we used the MICs of the other azoles to classify isolates as phenotypically azole WT or non-WT using the ECOFFs of voriconazole, itraconazole and posaconazole. As expected, using this method for the classification of isolates, the phenotypically WT isolates showed a WT isavuconazole MIC distribution, similar to previously published distributions. 27 In addition, specific point mutations of the cyp51A gene result in specific resistance phenotypes. 28 We found that the resistance mechanisms TR 34 /L98H and TR 46 /Y121F/T289A show a distinct pattern of resistance for isavuconazole too, with a distribution similar to that of voriconazole. This pattern of resistance might be due to the similarity in the chemical structures of isavuconazole and voriconazole since they lack the long tail of posaconazole and itraconazole. Probably, mutations in cyp51A affect the docking of isavuconazole in a similar manner to voriconazole, resulting in a high correlation in resistance phenotype. Isavuconazole susceptibility and PTA of A. fumigatus JAC For our clinical isolates, a very strong correlation was found for voriconazole and isavuconazole for the non-WT subgroup, and thus A. fumigatus isolates with an increased voriconazole MIC have a high probability of having an increased isavuconazole MIC. These results confirm previous findings. 15, 29 The correlation was strongest for isolates with the TR 34 /L98H and TR 46 /Y121F/T289A mutations, but was also found for WT isolates. Non-WT isolates with other mutations showed a lower agreement (73.3%), indicating that the correlation and agreement is influenced by the underlying azole resistance mutation and thus precluding extrapolation of isavuconazole susceptibility from the voriconazole MIC. However, most isolates in our study that were resistant to itraconazole or posaconazole but exhibited low voriconazole MICs did have a high probability of having a low isavuconazole MIC too. For example, we found one isolate that had the mutation at locus G54. Isolates with this mutation are often still susceptible to voriconazole; this isolate had an isavuconazole MIC of 1 mg/L, which is at the clinical breakpoint for susceptibility of isavuconazole. Of the seven isolates that had a voriconazole MIC of 1 mg/L, one had an isavuconazole MIC of 0.5 mg/L, three of 1 mg/L, one of 4 mg/L, one of 8 mg/L and one of .16 mg/L. Thus, non-WT isolates that are susceptible to voriconazole exhibit variable isavuconazole phenotypes. Isolates with an increased MIC of itraconazole and posaconazole were less likely to be cross-resistant to isavuconazole.
Isolates with the TR 34 /L98H and TR 46 /Y121F/T289A mutations are emerging globally and can be found in both the environment and in patients with invasive aspergillosis. [30] [31] [32] This study strongly indicates that isavuconazole cannot be used for the treatment of isolates harbouring these resistance mechanisms. However, several non-WT resistant isolates were not cross-resistant to isavuconazole, and isavuconazole might still be a treatment option, although MIC testing would be required.
As the isavuconazole ECOFF is one 2-fold dilution step higher than the EUCAST clinical breakpoint, a small proportion of the WT isolates would be classified as isavuconazole resistant. In our dataset, this was the case for 25 of 279 isolates (9%). Although these isolates do not harbour a triazole resistance mutation, they were classified as non-WT. WT A. fumigatus isolates with an isavuconazole MIC of 2 mg/L have a PTA with an isavuconazole standard dose of $75% (Figure 4 ) when the 90% exposure index (EI 90 ) is used as the endpoint. As the efficacy of isavuconazole was shown to be concentration related and AUC/MIC dependent, 12-14 patients infected with an isolate with an elevated isavuconazole MIC might benefit from dose escalation, even though a clinical study showed no relationship between exposure and response. 33 However, this lack of relationship is likely due to the fact that the patients in the clinical study did not harbour resistant isolates. Given the notorious difficulty or even impossibility of showing differences in susceptibility between strains within a WT population, an increase in dose might potentially benefit all patients.
It should be realized, however, that the pharmacodynamic target determined using in vitro and animal models is dependent on which model is used for determining the target exposure. Furthermore, the EI endpoint of animal models that translates best to the clinical response in humans is not well characterized. Currently, three animal studies determining the pharmacodynamic target of isavuconazole for invasive aspergillosis have been published. Lepak et al.
14 showed a strong relationship between the pharmacodynamic index AUC 0-24 / MIC and treatment outcome. This was also found by Seyedmousavi and EI 90 ), described as AUC 0-24 /MIC, were derived from Seyedmousavi et al.
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The target AUC 0-24 was calculated for isavuconazole MICs ranging between 0.25 and 8 mg/L. The correlated C trough s were then determined using a function describing the correlations between C trough and AUC 0-24 at steady state. These C trough s can be used for therapeutic drug monitoring when indicated.
Buil et al.
et al. 12 The target AUC 0-24 /MIC from the latter study was used here to derive the PTA and for the establishment of the C trough targets. 12 Furthermore, Petraitis et al. 13 determined the pharmacokinetic parameters in an experimental model of invasive pulmonary aspergillosis using neutropenic rabbits and correlated the variables with the in vivo efficacy. All three animal models show a clear dose-dependent response. [12] [13] [14] Using the pharmacokinetic/pharmacodynamic targets of Seyedmousavi et al., 12 our PTA for alternative higher dosing regimens suggests that, by increasing the dose, isavuconazole might be an option for the effective treatment of patients infected with an A. fumigatus isolate with an isavuconazole MIC of 2 mg/L. Results of the Monte Carlo simulations indicate that doubling the standard dose would result in a PTA of .90% when the EI 90 was used as target. Our results furthermore indicate that isavuconazole treatment of infection due to isolates with an isavuconazole MIC of 4 mg/L is not feasible if the doses used are those used for simulation in this study.
We have chosen day 28 of therapy to determine the relationship between AUC 0-24 and C trough . Using day 28 of therapy does reflect the purest situation in which steady state is obtained but using other timepoints could be justified as well. As AUC 0-24 is driven primarily by clearance and C trough is largely driven by clearance (as well as volume of distribution) we do not expect the relationship to change substantially over the course of therapy as the volume of distribution will not change. Some accumulation will occur but this is minimal owing to the loading dose given. The impact on the AUC 0-24 -C trough relationship will be negligible in our opinion. However, when analysing samples for therapeutic drug monitoring that are taken before reaching steady state at day 25-28, the AUC 0-24 /C trough can be expected to increase another 15%-30% when a sample is taken after 7 days of isavuconazole therapy and 5%-15% after 14 days of therapy based on our simulations and the data provided in the FDA briefing document. 34 An international expert panel recommended moving away from triazole monotherapy in patients with azole-resistant invasive aspergillosis, favouring liposomal amphotericin B or triazole and echinocandin combination therapy. 8 We previously found that low-level voriconazole-resistant A. fumigatus, i.e. voriconazole MIC 2 mg/L, and low-level posaconazole-resistant A. fumigatus, i.e. posaconazole MIC 0.5 mg/L, could be treated with voriconazole or posaconazole, respectively, provided that higher doses are administered, aiming to achieve higher pharmacodynamic targets compared with azole-susceptible infection. 33 Our current study indicates that high-dose isavuconazole treatment might also be an option in patients infected with an A. fumigatus isolate with an isavuconazole MIC of 2 mg/L. Dosages up to 400 mg once daily were shown to be safe and tolerable in a small group of neutropenic patients with AML. 35 However, high-dose isavuconazole treatment in azole-resistant invasive aspergillosis requires extreme caution owing to possible toxicity and drug interactions and would require intensive therapeutic drug monitoring and imaging. Nonetheless, given the limited alternative treatment options in azole-resistant invasive aspergillosis, high-dose isavuconazole therapy might be an option in selected patients.
